AHSG and metabolic dysfunction-associated steatotic liver disease: Patients with CAD were significantly younger, had lower HOMA-IR, less frequently had T2D and NAFLD (NAFLD prevalence 42% vs. 59%, p = 0.065; median (IQR) US-FLI 0 (0–3) vs. 2 (0–4), p = 0.038), but higher total cholesterol and Fetuin-A values (378 (124–662) vs. 236 (111–461), p < 0.001) than PAD patients.